Skip to content

Etravirine

    Brands

    DEA Class; Rx

    Common Brand Names; Intelence

    • HIV, NNRTIs

    Non-nucleoside reverse transcriptase inhibitor (NNRTI)
    Used with other antiretroviral drugs to treat HIV-1 infections in treatment-experienced patients 2 years and older
    Associated with severe and potentially life-threatening rashes

    Treatment of HIV-1 infection in combination with ≥2 additional antiretroviral agents in treatment-experienced patients exhibiting viral replication with documented non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance

    —

    • Rash (16.9%)
    • Nausea (13.9%)
    • Increased LDL (13%)
    • GI disorders (2.3-5.2%)
    • Fatigue (3.3%)
    • Peripheral neuropathy (4%)
    • Increased creatinine (2%)
    • Diarrhea (2%)
    • Stevens-Johnson syndrome
    • Erythema multiforme
    • Angina
    • Angioedema
    • Toxic epidermal necrolysis (including reports of fatalities)
    • Hypersensitivity reactions (including cases of hepatic failure)

    Hypersensitivity

    Risk of severe skin reactions (eg, Stevens-Johnson Syndrome, erythema multiforme, toxic epidermal necrolysis)

    Hypersensitivity reactions including drug rash with eosinophilia and systemic symptoms (DRESS) reported; characterized by rash, constitutional findings, and sometimes organ dysfunction; discontinue if severe rash develops and initiate appropriate therapy

    Risk of immune reconstitution syndrome

    50% decrease in absorption when administered under fasting conditions: only take with meal

    Etravirine use during pregnancy evaluated in a limited number of individuals as reported by the APR, and available data show 1 birth defect in 66 first trimester exposures to etravirine-containing regimens

    The Centers for Disease Control and Prevention recommend HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV

    Based on limited data, etravirine has been shown to be present in human breast milk

    Adults

    400 mg/day PO.

    Geriatric

    400 mg/day PO.

    Adolescents

    weighing 30 kg or more: 400 mg/day PO.
    weighing 25 to 29 kg: 300 mg/day PO.

    Children

    2 to 12 years weighing 30 kg or more: 400 mg/day PO.
    2 to 12 years weighing 25 to 29 kg: 300 mg/day PO.
    2 to 12 years weighing 20 to 24 kg: 250 mg/day PO.
    2 to 12 years weighing 10 to 19 kg: 200 mg/day PO.
    less than 2 years or less than 10 kg: Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Etravirine

    tablet

    • 25mg
    • 100mg
    • 200mg